

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/061449 A1

(51) International Patent Classification⁷: **C07C 405/00**,
59/90, A61K 31/5575, 31/192, A61P 37/00

(21) International Application Number:
PCT/GB2004/005421

(22) International Filing Date:
22 December 2004 (22.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0329620.9 22 December 2003 (22.12.2003) GB
60/531,979 24 December 2003 (24.12.2003) US
60/622,012 27 October 2004 (27.10.2004) US

(71) Applicant (for all designated States except US): **PHARMAGENE LABORATORIES LIMITED** [GB/GB]; 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BORMAN,**


Richard, Anthony [GB/GB]; Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **COLEMAN, Robert, Alexander** [GB/GB]; Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **CLARK, Kenneth, Lyle** [GB/GB]; Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **MILLS, Keith** [GB/GB]; Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **OXFORD, Alexander, William** [GB/GB]; Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **ZHANG, Jian** [GB/GB]; Pharmagene Laboratories Limited, 2 Orchard Road, Royston Hertfordshire SG8 5HD (GB). **DUFF, Peter, Thomas** [GB/GB]; Target Molecules Limited, 49 Granby Grove, Highfield, Southampton Hampshire SO17 3RY (GB).

(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

[Continued on next page]


(54) Title: EP₂ RECEPTOR AGONISTS



(iv)



(iii)



(57) Abstract: A compound selected from Formula (iv) or Formula (iii); (iv) (1R,2S)-2[4-1(S)-hydroxyhexyl]phenyl]-5-oxo-cyclopentaneheptanoic acid [RSS] or (iii) (1R,2S)-2[4-1(R)-hydroxyhexyl]phenyl]-5-oxo-cyclopentaneheptanoic acid [RSR] or a salt, solvate, chemically protected form or prodrug thereof, and its use in treating conditions alleviated by agonism of an EP₂ receptor.



CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.